

# All.Can nine years

**Annual Report  
2025**

## Mission

**All.Can is the global multi-stakeholder platform for cancer care efficiency, aiming to improve health outcomes for cancer patients around the world.**

We collaborate to advance efficiency in cancer care for the benefit of patients and society.

We do so by generating, promoting and advocating for evidence-based and measurable improvements in cancer care research, policy and practice.

## Vision

**We imagine a world in which patients are always at the heart of cancer care.**

**We work together for efficient, equitable and sustainable cancer care that focuses on what matters to patients and society.**

## All.Can's work is guided by three Key Principles:



### **Put patients first**

Define and deliver cancer care efficiency according to what matters most to patients and society.



### **Adopt a whole-system perspective**

Eliminate inefficiencies across the entire cancer care pathway and spectrum.



### **Promote multi-stakeholder collaboration**

Harness the strengths of all cancer care stakeholders.

# Contents

<b>Foreword</b>	<b>4</b>
<b>Key Achievements in 2025</b>	<b>6</b>
Advancing Cancer Care Efficiency: Key Milestones and Strategic Actions from All.Can International in 2025	8
From guidance to practice: implementation and uptake of the Action Guide	9
Strengthening Partnerships for Greater Impact in Cancer Care	10
Advocacy, Endorsements and Policy Alignment	11
Contributions to European policy processes	12
Highlights of All.Can participation at events in 2025	13
<b>Members</b>	<b>16</b>
<b>National Initiatives</b>	<b>17</b>

All.Can International is a not-for-profit organisation (ASBL) registered in Belgium.

Its work is made possible with financial support from Bristol Myers Squibb, Roche, MSD, Johnson & Johnson, Pfizer, Astellas, and Daiichi Sankyo, among other funding means.

# Foreword

## 2025 marked All.Can's ninth anniversary and another year of intense engagement and collaboration to advance our strategic goals worldwide.

All.Can remains committed to improving health outcomes for people affected by cancer around the globe through policy research and strategic advocacy.

Our work is guided by a clear vision: accessible, patient-centred, evidence-based and high-quality cancer care. We strive for efficient, equitable, and sustainable systems that focus on what matters most to patients and society.

Collaboration is central to All.Can's impact. In 2025, we deepened engagement with partners across the cancer landscape to drive progress toward adaptive healthcare systems and more equitable use of resources, now and in the future.

- In 2025, All.Can transitioned from development to implementation of the Cancer Care Efficiency Action Guide through demonstration projects launched in three National Initiative countries: Australia, Greece and Mexico. We carried out an outreach and engagement programme with key decision-makers, including the publication of an article on All.Can's *Action Guide* in the Elsevier *Journal of Cancer Policy*, and ran a media campaign via Euractiv that generated over one million impressions across their website and social media channels alone.
- Our 2025 flagship project on person-centred cancer care pathways continued to develop and we will publish a policy report shortly outlining current challenges, successful case studies, and actionable recommendations.
- Our National Initiatives network also advanced a range of new and innovative projects worldwide, including projects such as All.Can Mexico's high-level roundtable on early cancer detection and care, All.Can Israel's conference on inequalities in cancer care, and All.Can Belgium's roundtable on innovation across the cancer pathway focusing on patients and society.
- We continued to foster multi-stakeholder dialogue and policy development through EU-funded projects: 4PCan, where All.Can leads policy recommendations for primary prevention, and CURTAIN, where we provide guidance on cancer literacy policy actions. In partnership with EFPIA, we rolled out and completed collaboration on EU screening recommendations in six countries: Spain, Italy, Belgium, Romania, Poland and Sweden.
- The All.Can Efficiency Hub continued to grow with new national case studies, and it was referenced in the European Parliament report on the implementation of Europe's Beating Cancer Plan.
- All.Can was also active in Mission Early – an initiative to advance early cancer detection and care – and engaged in work with the Organisation for Economic Co-operation and Development (OECD), alongside ongoing partnerships with Sharing Progress in Cancer Care (SPCC), the European Alliance for Value in Health (EUHC), and the Union for International Cancer Control (UICC).

All.Can's strategic goals remain clear: to advance thought leadership, facilitate meaningful dialogue and policy change, and improve systems and care pathways at both global and national levels, ultimately improving outcomes for all those affected by cancer.

Looking ahead to 2026, All.Can will focus on raising awareness of our work and on the dissemination and implementation of our projects worldwide. We aim to further engage key stakeholders across health systems and the cancer community, leveraging our members, National Initiatives and partnerships in our shared commitment to shaping policy and improving outcomes for patients.



**Christobel Saunders**

President,  
All.Can International




**Eduardo Pisani**

Chief Executive Officer,  
All.Can International

# Key Achievements in 2025

## Advancing thought leadership

### Action Guide for Efficient Cancer Care



Demonstration projects in

**3** countries

Euractiv report

**3** articles

**1mil** impressions

Social media campaign

**25** posts **5.5k** impressions

### EU-funded projects

4P-CAN, on Primary Cancer Prevention

CURTAIN, a virtual cancer literacy library

### SPCC (Sharing Progress in Cancer Care) Webinars

Focusing on efficiency implementation in the cancer care continuum, with leading experts and policy makers. Launched Q1/2025.

**3** online educational modules

**1** live webinar

## Improving systems and pathways

### Efficiency Hub

**5** new case studies

**+11k** page visits

### National Initiatives Programmes

**14** countries

### 4 New Members

Children's Tumor Foundation (CTF) Europe

FUNSALUD (Fundación Mexicana para la Salud)

Pfizer

Uganda Alliance of Patients' Organisations (UAPO)

### Promoting implementation of Cancer Screening Programmes

**6** EU countries



Spain



Belgium



Poland



Italy



Romania



Sweden

**9** events

**600** participants

**100** speakers

**2** NCCP contributions

## Driving policies and dialogue

### Policy contributions

2

for European Parliament (women's health and rare diseases)

1

for Irish Presidency Programme

8

Amendments for Health Workforce file in the European Parliament

### "Mission Early" Advisory Board role & pilot projects

Advancing Early Cancer Detection and Care



Mexico



Romania



Spain

### Ongoing Partnerships



UICC



EU Health Coalition




European Alliance for Value in Health



Development of person-centred cancer care pathways policy report

THE LANCET  
Oncology

Contribution to *The Lancet Oncology* on UK NCCP



Annual Report  
All.Can @8

### LinkedIn

31k  
impressions

14% ↑  
new followers

1,432  
page views



21  
representation opportunities

# Advancing Cancer Care Efficiency: Key Milestones and Strategic Actions from All.Can International in 2025

In 2025, All.Can International strengthened its role as a global, multi-stakeholder platform for cancer care efficiency by moving decisively from **evidence generation to implementation support and policy uptake**. Building on All.Can's established definition of efficiency and its suite of evidence-based resources, the year centred on three priorities.

First, accelerating the real-world implementation of the Action Guide for Efficient Cancer Care through country pilots. Second, positioning prevention, early detection and cancer literacy as core enablers of efficiency through EU-funded consortia and aligned policy engagement. Third, amplifying the voices of patients and clinicians

to ensure that discussions on sustainability and system performance remain anchored in what matters most to people affected by cancer.

Europe continues to face a widening gap between a growing cancer burden and constrained health system capacity. 2025 activity reflected a clear message across All.Can's partnerships and public affairs work: **Improving efficiency is not a cost-cutting agenda**. It is a quality and outcomes agenda, requiring better data, clearer pathways, stronger coordination, and meaningful patient involvement.

**"In 2025, All.Can demonstrated that improving cancer care efficiency is about delivering better outcomes for patients through smarter, more coordinated systems. By moving from evidence to implementation, strengthening prevention and early detection - including through radiotherapy - and ensuring patient and clinician voices remain central, we are supporting health systems in delivering tangible, measurable improvements in cancer care."**

**Darien Laird**, All.Can Board Member and Executive Director, Global Coalition for Radiotherapy



# From guidance to practice: implementation and uptake of the Action Guide

In 2025, All.Can advanced the **implementation and dissemination of the Action Guide for Efficient Cancer Care as a single, integrated effort** linking national pilots with targeted policy and digital outreach to drive adoption. Implementation progressed in three countries, demonstrating the *Guide's* adaptability across different levels of system readiness. Australia conducted its preparedness assessment to inform recommendations in early 2026; Greece launched its national *Action Guide* report in November 2025, engaging eight **hospitals and around ten stakeholder groups**; and Mexico completed interviews and preliminary analysis, with validation and consensus-building planned for early 2026.

Dissemination activities were designed to reinforce implementation and accelerate policy uptake. A dedicated [Euractiv Advocacy Lab campaign](#) positioned the *Action Guide* as a practical roadmap for policymakers, delivering **three articles and one special report** and generating **over one million impressions**. The **Efficiency in Action** digital campaign (July–December 2025) complemented the Euractiv campaign by showcasing how the *Action Guide* metrics can be implemented in real world through national case studies, publishing **25 posts**, which achieved **5,500+ impressions**, with the highest engagement driven by real-life implementation examples. Across both channels, dissemination was directly informed by pilot experience in Greece, Australia and Mexico, supporting momentum, policy uptake and cross-country learning.

## Making efficiency visible and actionable

In 2025, All.Can invested in approaches that make efficiency more accessible to decision-makers and stakeholders beyond specialist audiences.

- A dedicated [series of interviews](#) with patients and clinicians captured real world experiences of delays, fragmentation, and navigation challenges, translating these insights into advocacy assets and digital content.
- All.Can continued to position efficiency as a system-wide performance dimension that requires improvement across the full pathway, from prevention and early detection through diagnosis, treatment, survivorship and end-of-life care.



# Strengthening Partnerships for Greater Impact in Cancer Care

Partnerships remained central to All.Can's operating model in 2025. All.Can continued to work across the cancer ecosystem, bringing together patient organisations, clinicians, researchers, policymakers and industry to support implementation and policy uptake.

In 2025, All.Can International concluded a three-year project in **collaboration with the EFPIA Oncology Platform**, where All.Can co-developed actions to support implementation of the EU Council Recommendation on cancer screening. The work spanned six EU Member States and delivered six country reports distilled into two annual reports and hosted nine events with 600+ attendees and 100 speakers, including National Cancer Control Plans contributions (Sweden, Spain).

Driven at the national level by All.Can's National Initiatives in Belgium, Italy, Poland, Romania (InoMed), Spain and Sweden, the collaboration reached a broad policy and stakeholder audience and was used as a practical reference in discussions with EU institutions and national authorities. It reinforced All.Can's consistent message that screening policy success depends not only on coverage targets, but on system readiness, workforce capacity, and the ability to ensure timely follow-up and treatment.

## Contribution to *The Lancet Oncology*

A further milestone in 2025 was All.Can's contribution to *The Lancet Oncology* on national cancer control planning in the UK. Drawing on lessons from Denmark, Italy and Canada, the commentary argued that effective cancer plans require policy discipline, prioritisation and accountability across the

full cancer pathway, positioning efficiency as fundamental to improving outcomes and system sustainability through enforceable patient rights, transparent indicators, and better organisation of care alongside responsible use of workforce capacity and data.

## EU funded consortia: prevention and literacy

All.Can's leadership within EU-funded consortia strengthened its engagement with European stakeholders and reinforced prevention and literacy as critical enablers of efficient and equitable systems.

### 4P-CAN

4P-CAN addresses personalised prevention, and All.Can leads on delivering policy recommendations for primary prevention, including support for adoption of the European Code Against Cancer in five European countries.

### CURTAIN

CURTAIN kicked off in September 2025 and focuses on improving cancer literacy in Europe. All.Can will support the development of a digital library of resources to inform the public and contribute to recommendations for policy action on cancer literacy. The project reinforces the link between literacy, navigation and shared decision-making.



## Advocacy, Endorsements and Policy Alignment

All.Can's advocacy in 2025 focused on embedding efficiency within broader policy debates on equity, sustainability and system performance.

All.Can formally endorsed the **UICC World Cancer Declaration 2025–2035**, aligning with its principles of equity, evidence, sustainability and accountability. All.Can highlighted efficiency as a critical enabler of the Declaration's goals, particularly in prevention and early detection, interoperable data ecosystems, person-centred care and accountable investment.

In 2025, All.Can also endorsed the [Mission Early Call to Action for Better Early Cancer Care](#), launched at the World Cancer Leaders' Summit in Melbourne. The Call to Action reinforces the importance of early detection, timely diagnosis and coordinated care as prerequisites for improving outcomes and reducing avoidable

inefficiencies across cancer pathways. All.Can's endorsement reflected its long-standing focus on prevention and early action as core components of efficient, people-centred cancer care.

All.Can also endorsed the **World Federation of Public Health Associations (WFPHA) Call to Action on Life-Course Immunisation**, recognising immunisation as a critical component of prevention strategies that support sustainable and resilient health systems, including for cancer and other non communicable diseases



**“By collaborating with a wide range of stakeholders, including EU consortium partners and All.Can national initiatives, such as our own initiative in Greece, All.Can helps ensure that cancer policies, screening programmes, prevention strategies and literacy initiatives are not only well designed, but also supported by the system readiness, workforce capacity and accountability needed to deliver timely, high-quality care for patients.”**

**George Kapetanakis**, All.Can Board Member and Director of All.Can Greece

## Contributions to European policy processes

In early 2025, the European Parliament Committee on Public Health (SANT) launched consultations on rare diseases and women's health. All.Can provided responses informed by its global community and evidence base, highlighting the importance of timely diagnosis, equity, access to innovation, patient-centred pathways and sustainable investment supported by data-driven accountability.

All.Can provided substantive input to the **EU health workforce report**, submitting amendments on retention and recognition of advanced roles, reducing administrative

burden and explicitly linking workforce planning to continuity, quality and efficiency of care, and cancer literacy as a policy issue as well as a public communication need.

This engagement reinforced All.Can's position that improvements in timeliness, coordination and patient-centredness depend on a supported, skilled and sustainably planned workforce.



# Highlights of All.Can participation at events in 2025

All.Can maintained a strong presence at European and global events in 2025, using these platforms to advance the efficiency agenda, build partnerships, and reinforce policy alignment.

Selected highlights included:

- **UICC World Cancer Leaders' Summit 2025 (Melbourne)**, contributing to discussions on early cancer care, equity, prevention and the launch of the Mission Early Call to Action for Better Early Cancer Care.
- **Prevention-focused policy dialogues**, contributing All.Can perspectives on prevention, early detection and system sustainability.
- **National parliamentary and stakeholder briefings** across several countries, linking cancer care efficiency with innovation, digitalisation, governance, workforce capacity, literacy and navigation.
- **Milestone national implementation events**, including the **Greece Action Guide report launch on 12 November 2025**, bringing together hospitals, policymakers, clinicians and patient organisations to validate recommendations and support uptake.

Together, these engagements strengthened All.Can's convening power and reinforced a consistent message in all settings. Efficiency is an outcome-driven agenda, requiring coordinated action across stakeholders that is supported by evidence, metrics and real-world implementation learning.

## Looking ahead

By the end of 2025, All.Can had consolidated its shift from evidence generation to implementation, policy integration and

knowledge mobilisation. Building on *Action Guide* pilots, prevention and literacy initiatives, targeted advocacy and integrated dissemination, 2026 will focus on scaling adoption and demonstrating measurable system improvement.

This momentum will be marked by the launch in March 2026 of *Person-centred cancer care: Improving outcomes, experiences and efficiency*, which will position person-centred cancer care pathways as a unifying framework to improve outcomes for people with cancer while strengthening efficiency, resilience and sustainability across health systems. The report will support deeper engagement with policymakers and health system leaders, reinforcing the translation of evidence into action grounded in what matters most to people living with cancer.

**"Through our active engagement at major European and global events in 2025, All.Can reinforced that cancer care efficiency is an outcome-driven agenda. By convening policymakers, clinicians, patients and system leaders around evidence and real-world implementation, we are helping align priorities and translate dialogue into coordinated action."**

**Ebba Hallersjö Hult**, All.Can Board Member and Vision Zero Cancer Co-Founder and Head



## Highlights of All.Can participation at events in 2025:

16 January 2025

**All.Can Poland Annual Meeting** –  
Eduardo Pisani

22 January 2025

**Breast Gynecological & Immunooncology International Cancer Conference** –  
Matti Aapro

1 April 2025

**4P-CAN Annual Consortium Meeting** –  
Mădălina Iamandei

9 May 2025

**AIOM & IQN Path 13th meeting on external quality assessment in molecular pathology** –  
Ebba Hallersjö Hult

8-11 May 2025

**European School of Oncology: Improving Cancer Outcomes and Leadership** –  
Eduardo Pisani

12 May 2025

**All.Can AGM**

10-11 June 2025

**11th annual World Cancer Series Europe** –  
Ebba Hallersjö Hult

21 June 2025

**ECHoS Hub – Poland launch** – Aleksandra Rudnicka and Ewa Matusiak

24 June 2025

**ProMIS Workshop: 'Sinergie tra l'Italy e l'Europa nella Lotta contro il cancro'** –  
Eduardo Pisani

30 June–1 July 2025

**2nd Synergies Forum on Cancer Policy Research & Funding Strategies** –  
Matti Aapro

22 July 2025

**Innovative Therapies in Hematologic Cancers: Towards Equitable and Sustainable Access** –  
Italy's Senate,  
Eduardo Pisani

10 September 2025

**4P-CAN coordination meeting** –  
Mădălina Iamandei and Angela Meurer

11 September 2025

**CURTAIN kick-off meeting** –  
Mădălina Iamandei and Angela Meurer

29 September 2025

**Prevention & Early Detection Cluster Meeting** –  
Mădălina Iamandei

17-20 October 2025

**Compassionate care in cancer nursing: Bridging the gap between science and humanity EONS18 @ ESMO** –  
Eduardo Pisani

4 November 2025

**IBTA 6th Biennial World Summit of Brain Tumor Patient Advocates** – Eduardo Pisani and Mădălina Iamandei



12 November 2025

**All.Can Greece: "Mapping the Efficiency of Cancer Care in Greece: Pilot Implementation of the All.Can ActionGuide"** – Eduardo Pisani

18 November 2025

**Global Health Connector Digital Summit 2025: Intelligence in Action: Proven Solutions Driving Transformation in Health Systems** – Eduardo Pisani



19-20 November 2025

**World Cancer Leaders Summit** – Christobel Saunders, AllCan President, Ebba Hult, (board member), Michael Oberreiter (board member)

4 December 2025

**European Cancer Forum** – Eduardo Pisani

5 December 2025

**2025 Global Forum: Creating Health Through Understanding and Personalising Value** – Christobel Saunders and Mădălina Iamandei



# Members

All.Can International's membership reflects its multi-stakeholder representation and includes experts from patient organisations, policymakers, healthcare professionals, researchers and industry. Its 34 organisational and eight individual members contribute their unique knowledge and expertise to improve

efficiency in cancer care, act as ambassadors for All.Can, and help to publicise its work, events, publications and research findings.

We welcomed four new organisational members last year:



**Children's Tumor Foundation (CTF) Europe** is an international nonprofit organisation driving research, innovation, and patient support in neurofibromatosis (NF1, NF2, and schwannomatosis).



**FUNSALUD (Fundación Mexicana para la Salud)** is a think tank that has been able to position in the public policy agenda proposals that have helped develop the Mexican Healthcare System.



**Pfizer** is a leading global biopharmaceutical company committed to discovering, developing, and delivering innovative medicines and vaccines that improve lives.



**Uganda Alliance of Patients' Organisations (UAPO)** is a patient-driven not-for-profit civil society organization that leads the patients voice founded in 2011.


# National Initiatives

By the end of 2025, All.Can proudly recognised 14 countries that have launched multi-stakeholder National Initiatives, tailoring the All.Can mission to local contexts and advancing its objectives.

This last year, All.Can National Initiatives have diligently worked to unite stakeholders, identify healthcare system needs and challenges, develop policy recommendations, and advocate for their inclusion in national cancer plans and policies.

These initiatives have shared experiences, achievements, and best practices through regular meetings of the All.Can National Initiative Working Group, as well as via the All.Can International website, newsletter, and social media.

Continue reading to learn how All.Can's National Initiatives are making headway to drive policy change in each of their countries.



● All.Can Initiative Established    ● All.Can Initiative in development



## Achievements in 2025

In 2025, All.Can Australia continued to strengthen its role as a collaborative platform to drive more efficient, patient-centred cancer care, with a strong focus on generating evidence to influence policy conversations.

A major milestone achieved was the progression a new patient research survey, revisiting the landmark 2018 global survey to assess whether the experiences of Australians affected by cancer have changed over time. [The new survey was launched nationally in August 2025 to collect experiences of people living with cancer and their carers](#), with the financial support of the Oncology Industry Taskforce (OIT), aiming to gather experiences from Australians across tumour types and geographies. The survey design aimed to uncover inefficiencies across diagnosis, treatment, navigation, support services and out-of-pocket costs. Analysis of the survey data will commence shortly. To date, close to 400 respondents have been secured.

All.Can Australia also advanced its contribution to global All.Can work through active participation in the All.Can Efficiencies Pilot. In 2025, we worked with a research partner, Biointelect, to conduct desktop research and stakeholder interviews. Early findings strongly reflected lived experience within the Australian system and confirmed that:

- When it comes to timeliness of care, Australia has strong foundational cancer care infrastructure including a national registry and EHRs. However, there are critical gaps in data integration, real-time monitoring, and systematic tracking of optimal care pathway compliance that limit the ability to ensure timely, high-quality cancer treatment.

- Despite significant federal investment in patient navigators and the establishment of Comprehensive Cancer Centres (CCC), Australia's cancer care coordination is undermined by fragmented workforce monitoring, inconsistent task-sharing regulation, incomplete population coverage by CCCs, and lack of standardised oncology nurse-to-patient ratios.
- While Australia has established frameworks for patient-reported measures and patient rights, implementation remains inconsistent with fragmented PROM/PREM collection, limited integration into EHRs, variable patient engagement in treatment decisions, and inadequate education services for culturally diverse and regional populations.

The full report detailing key findings and recommendations will be made publicly available in the coming months.

In parallel, All.Can Australia's Board members remained actively engaged in national policy discussions, including through participation in the government-led Australian Cancer Nursing and Navigation Program. These efforts are closely aligned with the Australian Cancer Plan and reinforce All.Can Australia's role as a trusted, evidence-based contributor to system-level reform.

Throughout the year, All.Can Australia maintained momentum by strengthening existing relationships and exploring new strategic partnerships, laying the groundwork for expanded impact in 2026.



## Achievements in 2025

Throughout 2025, All.Can Belgium strengthened its role as a multi-stakeholder platform supporting more efficient, patient-centred cancer care in Belgium. Our General Assembly served not only as a governance milestone but also as a moment for substantive policy dialogue, featuring an engaging panel discussion that included reflections on the development of a new Belgian National Cancer Plan.

In parallel, All.Can Belgium actively contributed to policy development by participating in a series of workshops organised by the Cabinet of the Minister of Public Health, sharing stakeholder perspectives to inform the upcoming national cancer strategy. We also convened a high-level parliamentary roundtable on innovation in cancer care at the Federal Parliament, bringing together policymakers, clinicians, researchers, health system experts and patient representatives to discuss how innovation can be better translated into improved outcomes for patients.

Beyond policy engagement, we continued our public awareness efforts through a targeted social media campaign focused on lung cancer, highlighting the importance of early detection and timely access to care. In addition, significant progress was made on our white paper on clinically meaningful endpoints in curative oncology, developed through extensive stakeholder consultation and debate.

Looking ahead to January, All.Can Belgium will host a dedicated event on clinically meaningful endpoints in curative oncology, alongside the official publication of the white paper. We are also advancing our "Get Checked Early" awareness initiatives, with an initial focus on HPV-related cancers, aiming to support prevention and early diagnosis as key levers for improving cancer outcomes.





## Achievements in 2025

In 2025, All.Can Canada (ACC) strengthened its governance and continued to advance equitable, swift, and appropriately delivered cancer diagnosis across Canada.

ACC approved a new **3-Year Strategic Plan (2025–2027)** and refined its operational planning to align priorities around equity, evidence-informed pathways, and system transformation. To improve agility and outcomes, ACC transitioned to **project-focused working groups**, launching new initiatives in:

- Pathways
- Equity Learning Modules for Earlier Cancer Diagnosis
- Case Studies
- Ocular Melanoma Research

ACC expanded its evidence base by completing **four new system-level case studies**, bringing the national total to ten. These evaluated practices continue to inform policy dialogue, system redesign, and knowledge mobilization. Find all the papers on our website: <https://www.allcancanada.ca/>

- Timely Colorectal Cancer Diagnosis in Alberta (Revised)
- Rapid Investigation Clinic, Quebec
- Alberta Thoracic Oncology Program (ATOP)
- Predictive Biomarker Testing in Gastric & GEJ Cancer: A Pan-Canadian Consensus

ACC also advanced rare cancer research through its Ocular Melanoma Research Working Group, completing a national patient survey, conducting in-depth interviews, and drafting the first comprehensive Ocular Melanoma Diagnosis Research Report, alongside a two-year dissemination and knowledge-mobilization plan.

Throughout the year, ACC members and the Secretariat staff shared patient perspectives and system solutions across national and international forums, contributing to conferences, webinars, workshops, and policy discussions focused on diagnostic delays, equity, biomarkers, and primary care.

ACC continued to build strong relationships with provincial health leadership, national advocacy organisations, and cross-sector partners, supporting joint policy submissions, letters to decision-makers, and collaborative initiatives aimed at system transformation.

A major milestone in 2025 was the launch of **ACC's new, proprietary website**, strengthening national networking and cross-country knowledge sharing through enhanced resource access, engagement analytics, and communications infrastructure:


[Visit our new website](#)

## 2026 Outlook

In 2026, All.Can Canada will:

- Advance pathway development to support primary care providers in initiating cancer investigations more quickly, including readiness work for a lung cancer diagnosis demonstration project.

- Continue producing and sharing new case studies while encouraging adoption of existing evaluated practices across jurisdictions.
- Mobilise and disseminate findings from the Ocular Melanoma Diagnosis Research Report.
- Progress Equity Learning Modules using co-design, narrative oncology, and digital storytelling to address structural barriers to earlier diagnosis.
- Expand stakeholder outreach across provinces and provider associations.
- Broaden dissemination of ACC tools and resources.
- Strengthen engagement through its new website and enhanced communications strategy.
- Continue contributing patient perspectives to national data, digital health, and interoperability initiatives in collaboration with partners across Canada.





## Achievements in 2025

In 2025, All.Can Colombia consolidated its role as one of the country's leading multisectoral cancer coalitions and as a reference within the global All.Can network on advancing the efficiency agenda. Significant progress was achieved across **legislative advocacy, regulatory reform, international positioning, strategic partnerships, digital communications and knowledge management**.

All.Can Colombia contributed to **shape the national cancer agenda** by supporting the work of the Bicameral Special Commission on Cancer, creating a strategic framework for congressional action. In partnership with the National Cancer Institute, it promoted a bill introducing a mandatory early cancer detection module in all healthcare professional curricula. The bill is in its final congressional stages. The coalition also developed a National Technical Note on Cancer, pending submission to Congress. Together with five allied organisations, All.Can Colombia participated in the National and International Public Hearing on Cancer, strengthening civil society and patient representation following an invitation from Senator Carlos Julio González.

The coalition supported the development of Colombia's new Cancer Control Model and 10-Year Cancer Control Plan, participating in three working groups and acting as a bridge between the National Cancer Institute and civil society. These included: an opening group with the Interinstitutional Observatory of Adult Cancer, led with the Office of the Ombudsman, focused on evaluating public policy and quality of life; a regional working group in Antioquia with Fundación RASA, supporting patient navigation; and a patient-focused group with Fundación Retorno Vital, active in health promotion, prevention and access to care.

Through these engagements, **All.Can Colombia positioned prevention and early detection as core efficiency drivers** during a critical policy window, as the previous 2012–2021 Plan had not been updated.

**The coalition strengthened its technical base through partnerships** with Pontificia Universidad Javeriana, reinforcing research-informed policymaking. A collaboration was also established with the Embassy of the Kingdom of the Netherlands, recognised for facilitating international exchange and supporting training initiatives with the National Cancer Institute on best practices in cancer care.


**A tailored digital strategy was built on three pillars:** positioning efficiency as a cross-cutting theme, tracking cancer legislation and celebrating milestones through a multichannel approach. Content covered the Right to be Forgotten law, the national screening programme and the declaration of cancer as a public health priority, alongside updates on the Cancer Control Model and Plan. This generated 30.000 impressions.

Monthly newsletters enhanced **internal coordination and transparency**, while engagement in over 10 national and international cancer initiatives sustained the coalition's visibility within Colombia's cancer ecosystem.

## Outlook for 2026

With a new Congress taking office, All.Can Colombia will aim to collaborate with key stakeholders and inform forthcoming cancer policy measures. The coalition will translate All.Can's global efficiency framework into context-specific initiatives and advance a legislative agenda embedding efficiency in health policy (for instance, including Bill No. 603 of 2025 House – 014 of 2024 Senate) and promoting a jointly developed national early detection curriculum with the National Cancer Institute. Engagement with newly elected legislators will intensify through the Bicameral Special Cancer Commission, alongside advocacy linked to the Government's National Development Plan. In parallel, expanded digital health literacy and education, academic integration of All.Can tools and close alignment with All.Can International will accelerate the translation of evidence into more efficient, equitable and person-centred cancer care.

Follow All.Can Colombia on [LinkedIn](#) and [Instagram](#) for regular updates.





## 2025 - A Good Year for Progress with the Beating Cancer Plan

In 2025 All.Can Germany continued with the stakeholder discussion that began in November 2024. The first step was the 33. NZW Oncology Congress in Hamburg in January 2025, showing the All.Can flag and presenting the results of the late 2024 discussion comparing the EU Beating Cancer Plan with the National German Cancer Care Plan.

The second main activity in 2025 was publishing a white paper titled "Different Roles on the Oncology Patient Journey" with different contributions from the discussion about therapy over nursing, to pharmacy and caring communities from the patients' point of view.

This paper is also available from the All.Can secretary in Brussels in English and in German.

A very important and different view in this paper is based on a newly developed course in oncology nursing, that offers a new approach and different content compared with general nursing.

During the second half of 2025 All.Can Germany focused on two main events. We supported the University Clinic Cologne for the first International Caring Community Congress of the German speaking countries: Austria, Switzerland and of course, Germany. The excellent keynote speaker for this two-day congress was Allan Kellehear, a professor at Northumbria University who is key to the European Caring Community Movement.

Continuing the idea of collaboration between German-speaking countries, our main political event in Berlin in November connected Austria, All.Can Switzerland and All.Can Germany. We looked at the state of the art in adapting different National Cancer Plans; tried to identify what has been learned so far; and what the German National Cancer Plan' progress would be by the end of 2025, as reported by a representative of the German Ministry of Healthcare.

Although industrial sponsorship for All.Can Germany ended as 2025 closed, All.Can Germany continues; in January we began a broad discussion of our white paper at the 34.NZW with representatives of participating oncological pharmaceutical companies.



## Achievements in 2025

In 2025, All.Can Greece built upon the substantial groundwork established in previous years to further advance its mission of improving the efficiency, quality, and patient-centeredness of cancer care in Greece. The key strategic priorities for 2025 included:

- The wide dissemination and pilot implementation of the *All.Can Action Guide for Efficient Cancer Care*.
- Enhanced engagement with policymakers and clinical leaders to support evidence-based reforms in cancer care and improve patient outcomes.
- A focus on the practical measurement of cancer care efficiency, aimed at strengthening accountability and driving systemic improvements.
- The promotion of patient involvement and the integration of patient perspectives in the design of cancer care services.
- Pilot Implementation of the *All.Can Action Guide* (March–November 2025)

The flagship initiative of All.Can Greece in 2025 was the pilot implementation of the *All.Can Action Guide for Efficient Cancer Care*. This initiative included an assessment of the preparedness of the Greek health system to adopt core efficiency metrics in cancer care, as well as the development of viable, evidence-based recommendations.

The pilot project aimed to:

1. Assess the efficiency of oncology services in Greece through the examination of multiple health policies and performance indicators.

2. Evaluate the readiness of the health system to adopt standardised efficiency metrics, as defined in the *All.Can Action Guide for Efficient Cancer Care*.
3. Provide evidence-based and feasible recommendations for the integration of efficiency metrics into the provided cancer care.

The pilot was implemented in collaboration with the University of Piraeus and the University of West Attica under the scientific supervision of Professors Athanasios Vozikis and Kostas Athanasakis.

The findings highlighted both progress achieved and significant opportunities for further improvement in oncology care and the integration of cancer care efficiency metrics in Greece.

Progress has been made through stronger governmental commitment, improved digital infrastructure (including cancer registries and e-health systems), wider use of patient-reported outcome and experience measures (PROMs/ PREMs), adoption of multidisciplinary team practices, and active engagement of major oncology hospitals in structured performance assessments. However, critical gaps remain, including the lack of a comprehensive National Cancer Strategy with clear objectives and monitoring, fragmented quality and performance indicators, limited data interoperability across clinical sectors, and workforce challenges such as nursing and patient navigator shortages.

### **“Mapping the Efficiency of Cancer Care in Greece.” (Athens, 12 November 2025)**

The results of the pilot implementation were presented at a dedicated event held in Athens on 12 November 2025, entitled “Mapping the

Efficiency of Cancer Care in Greece.” The event served as a platform to:

- Showcase the pilot findings and policy recommendations.
- Facilitate constructive dialogue among policymakers, clinicians, researchers, and patient advocates.
- Raise awareness of performance challenges and highlight opportunities for essential system reforms aimed at improving cancer care efficiency in Greece.

Participants included representatives from regional health authorities, oncology units, academic institutions, healthcare professional organisations, patient associations, and industry partners.

A summary of the All.Can Pilot Implementation results and findings is available [here](#).

Further information regarding the 12 November event may be found [here](#). The final report is scheduled for publication in February 2026.



## All.Can Greece Survey on Cancer Patients' Perspectives (November–December 2025)

In November and December 2025, All.Can Greece developed and conducted a survey in collaboration with the Hellenic Cancer Federation and the University of Piraeus. The survey aimed to capture and highlight the priorities of cancer patients in Greece, drawing on patient-reported outcomes and experience measures (PROMs/PREMs).

Cancer patients from across Greece were invited to share their perspectives regarding:

- Their experiences and interactions with healthcare providers, and more broadly, with the Greek healthcare system.
- Their self-assessment of mental and physical well-being during and following cancer treatment, as well as their current quality of life.

The findings are intended to enhance understanding of patients' priorities and to support the development of targeted, effective interventions that respond to patients' real needs. The survey was designed in alignment with recent advancements in the collection and use of PROMs and PREMs within the Greek healthcare system. An informational event to present the survey findings is planned for March 2026. Further details regarding the survey are available [here](#).

## All.Can Greece reaches 23 members

In 2025 All.Can Greece was pleased to welcome two new members, Pfizer Hellas and Daichi Sankyo Greece, bringing the total number of individual members to 23. Both companies expressed strong interest in joining All.Can Greece and contributing to its program.



## All.Can Conference at the Knesset – World Cancer Day

On February 4, 2025, All.Can Israel marked World Cancer Day with a national conference held at the Israeli Parliament (the Knesset), co-led with Members of Knesset Yonatan Mashriki and Dr. Yasser Hajirat.

The conference focused on the rights of oncology patients and opened with parallel discussions in two parliamentary committees: the Health Committee and the Labor and Welfare Committee. This was followed by an NGO fair, where patient organisations and oncology-related initiatives presented their work, and concluded with a plenary session that included two panels: a patient and civil society panel, and a professional expert panel.

The conference elevated the issue of oncology patient rights on the public and parliamentary agenda, highlighted systemic gaps, and laid the groundwork for further policy actions throughout the year.

## Legislative and Policy Initiatives

Following the Knesset conference, All.Can Israel engaged throughout 2025 in parliamentary discussions, working meetings, and professional briefings with Members of Knesset, parliamentary advisors, and representatives of government ministries.

As part of this process, the organisation contributed to the advancement of legislative proposals and policy initiatives addressing diagnostic timelines, continuity of care, access to information and services, and system transparency, through ongoing dialogue with

decision-makers and professional stakeholders.

## All.Can Israel Website – Patient Information and Navigation

In 2025, All.Can Israel launched its national website, a dedicated digital platform for oncology patients, their families, and healthcare professionals. The website serves as a patient navigation tool along the cancer journey and provides reliable, accessible information on patient rights, support services, and patient advocacy organisations.

The platform functions as an infrastructure connecting policy, field-level implementation, and patient experience, helping reduce informational and bureaucratic barriers.

## All.Can Research on Mapping Gaps in Oncology

All.Can Israel is currently advancing a large-scale national research project aimed at mapping gaps across the entire oncology patient journey – from prevention and diagnosis to treatment and survivorship.

A dedicated questionnaire was developed over the last few months, and the study is now in its central phase of broad national dissemination. The research is led by Dr. Avi Zigdon, from the Department of Health Systems Management at Ariel University, in collaboration with the Assuta Research Institute and Ichilov Hospital.

## All.Can Innovation Incubator

The All.Can Israel Innovation Incubator was launched during the World Cancer Day conference in February 2025. The incubator is designed to accelerate initiatives aimed at reducing bureaucratic and systemic barriers in oncology care.

Numerous initiatives applied to the program, eight of which were selected to pitch before a multidisciplinary jury from the oncology ecosystem. Three initiatives were chosen to enter the incubator program, which provides professional mentorship and financial support. The incubator is currently underway, with projects at various stages of development toward implementation.

## Second Annual All.Can Israel Conference – Inequality and Disparities

The second annual All.Can Israel conference took place on December 1, 2025, in Tel Aviv, bringing together approximately 200 representatives from across the Israeli oncology ecosystem, including hospitals, health funds, government ministries, local authorities, academia, patient organisations, and the private sector.

The conference served as a working forum to identify disparities and develop solutions to reduce inequality along the oncology patient journey. Ideas were presented in four core areas: social periphery; geographic periphery; the Arab population; and the ultra-Orthodox population. Participants worked in cross-sector groups to refine, rank, and expand proposed solutions, and registered to take part in their implementation.

All.Can Israel is currently consolidating policy recommendations and advancing the selected solutions toward implementation.

## Public Awareness and Media Engagement

Throughout 2025, All.Can Israel worked to raise public awareness of cancer-related inequalities through media coverage, interviews, and opinion pieces in both general and professional outlets. This activity contributed to positioning the issue on the public and professional agenda and making policy challenges more accessible to the broader public.





## Achievements in 2025

The year 2025 represented a turning point for All.Can Italy, with substantial progress in both access to therapeutic innovation in oncohaematology and the strengthening of cancer prevention policies. Following a structured advocacy and awareness-raising effort directed at national institutions, including the Ministry of Health and Parliament, All.Can Italy progressively focused its activities at the regional level, recognised as pivotal for healthcare planning, service delivery, and the implementation of prevention and access-to-care policies.

In this framework, All.Can Italy prioritised the promotion and implementation of the European Recommendation on cancer screening, aiming to translate national and European policy guidance into consistent and effective actions across regions. A structured and ongoing dialogue was established with selected Regions identified as priority contexts, notably Piedmont and Apulia. This engagement pursued clearly defined objectives and generated concrete outcomes of institutional relevance.

At the regional level, All.Can Italy worked to expand the population eligible for screening programs, enhance and update screening pathways, and strengthen the involvement of patient associations in decision-making processes related to cancer prevention, fostering a participatory, patient-centred approach. In Apulia, All.Can Italy was formally heard by the Regional Health Committee during an institutional discussion focused on early diagnosis, attended by Regional Councillors and members of the Regional Executive. This hearing enabled a constructive exchange on challenges and opportunities related to screening implementation. In Piedmont, the dialogue helped reinforce awareness of cancer prevention as a strategic lever to improve healthcare

sustainability and reduce territorial inequalities, while promoting integration among health planning, professionals, and patient organisations.

This regional advocacy contributed to significant national policy developments. From 2026 onward, the Italian Government has planned the extension of age ranges for breast and colorectal cancer screening and the consolidation of the lung cancer monitoring program, further embedding prevention as a central pillar of the national health agenda.

In parallel, All.Can Italy advanced the debate on access to innovative therapies through the organisation, under the patronage of the Senate of the Republic, of the event Innovative Therapies in Haematological Cancers: Towards Equitable and Sustainable Access. The initiative convened policymakers, clinicians, researchers, and patient representatives to support the development of a healthcare system capable of integrating innovation while ensuring equity, sustainability, and personalised care. Participants included representatives from the Ministry of Health, AIFA, the Regions, Parliament, patient associations, scientific societies, and research institutions. The discussion highlighted key governance challenges and opportunities, including the proposal for a National Network for Oncohaematological Therapies and sustainable funding models.

Despite the transformative impact of therapies such as CAR-T and bispecific antibodies, access in Italy remains uneven due to territorial disparities, governance gaps, and economic and organisational constraints. Addressing these barriers — alongside strengthening prevention and early diagnosis — will remain a core priority for All.Can Italy in 2026, building on its ongoing advocacy, institutional dialogue, and multilevel collaboration.



## Achievements in 2025

The year 2025 was a turning point for All.Can Mexico. We moved beyond discussing the challenges in our health system to implementing real-world solutions that prioritise the patient.

In 2025, our work focused on three major pillars: high-level advocacy, supporting local scientific research, and testing global efficiency tools in Mexico.

### I. Mission Early: Closing the Gap in Women's Cancer

On September 30, we gathered at the UNAM School of Medicine for the Mission Early Colloquium, a strategic meeting between global leaders such as Dr. Cary Adams from the UICC and the heads of Mexico's top health institutes. We confronted a harsh reality: while cervical cancer is almost entirely preventable, 80% of women in Mexico still receive their diagnosis when the disease is already advanced.

However, the tone of the event was one of hope and action. We shared success stories such as "Alerta Rosa," which has proven it is possible to cut diagnosis times to just 39 days. We are now translating these discussions into a practical document and policy roadmap.

Our goal is to take these learnings and turn them into action to improve the national standard for every woman in Mexico, regardless of where she is treated.

### II. The All.Can Mexico Award: Investing in Local Evidence

Scientific progress requires resources, which is why we launched the third edition of the

All.Can Mexico Award. We invited the academic community to show us how to make cancer care more efficient, and the response was outstanding. We received 24 high-quality research proposals, each offering unique ways to optimise how we detect and treat cancer.

By offering a grant, we are empowering Mexican researchers to find data-driven solutions that fit our specific needs.

These projects will be evaluated by an independent panel of experts. We are excited to fund innovations in cancer efficiency that can be scaled up to improve prevention and long-term monitoring across the country.

### III. The Efficiency Action Guide: From Theory to Practice


Finally, we are taking the All.Can *International Efficiency Action Guide* and putting it to the test on Mexican soil. In a powerful alliance with Tecnológico de Monterrey and Tómatelo a Pecho A.C., we have moved into the field to identify exactly where our system is failing.

Through interviews with key decision-makers and a thorough analysis of national cancer registries, we are mapping out the bottlenecks that slow down care.

This pilot project is a vital bridge between international theory and the clinical reality our doctors and patients face every day.

The final report will do more than just strengthen our domestic policies; it will serve as a blueprint for our neighbours across Latin America.

At All.Can Mexico, we are proving that when we work together, we create a more sustainable and equitable future for everyone.



## Achievements in 2025

The year 2025 marked important organisational changes for All.Can Poland. Following the completion of his four-year term of office, Szymon Chrostowski, from the Wygrajmy Zdrowie Foundation, was succeeded by Aleksandra Rudnicka, Spokesperson of the Sanitas Oncology Association, who assumed the role of Chairwoman of the Presidium.

The past year also brought a significant expansion of the initiative. All.Can Poland welcomed 20 new members, including medical experts, representatives of Polish Parliament, patient organisations, and media partners, increasing the total number of members to 63. This growing and diverse membership further strengthens the initiative's interdisciplinary character and its ability to foster dialogue between patients, clinicians, policymakers, and other key stakeholders in oncology and haematology.

One of the year's key achievements was the preparation and wide dissemination of the next edition of the report *Diagnosis of Changes in Oncology and Haemato-Oncology Care in 2024*, which provided a comprehensive assessment of system-level developments, progress made over the year, and remaining challenges and unmet needs that patients face. The report was broadly medialisised and contributed to public and expert discussions on the direction of oncological and haemato-oncological care in Poland. The report is available on the [All.Can Poland website](#):

Another important milestone was the publication of the report *Oncological Preventive Programs Implemented in Poland in 2022–2024*, which analysed the availability, popularity, and

effectiveness of cancer screening and prevention programs. The report highlighted key barriers to participation and underlined the importance of strengthening prevention, early detection, and health education as integral elements of cancer care. The [report is available to read](#) on the All.Can Poland website.

Both publications were shared with key stakeholders and decision-makers, including representatives of the Ministry of Health, the National Health Fund, health agencies, and members of parliament, supporting evidence-based dialogue on system improvements.

## 2026 Outlook

In 2026, All.Can Poland plans to further intensify its analytical and expert activities. In February and March, the Initiative will publish and actively promote two major reports.


The first will be *Diagnosis of Changes in Oncology and Haematology Care in 2025*, continuing the annual monitoring of system reforms and their impact on patients' access to timely, high-quality care.

The second publication will focus on haematology: *Individualisation of Therapy as the Basis for Optimising the Treatment of Haematology Patients*. This report has been developed in close cooperation with more than a dozen leading medical experts from across Poland and addresses the role of personalised treatment approaches in improving clinical outcomes and quality of life for patients with haematological diseases.

All.Can Poland also plans to carry out further expert projects, including work on the report *Directions for the Development of Oncology and Haematology*, the aim of which will be to identify key priorities and recommended directions for change within the healthcare system, with a view to improving the quality of treatment and patient experience.

Alongside these publications, All.Can Poland will continue its communication and advocacy efforts through its website and social media channels, including LinkedIn, X, and Facebook, to disseminate key findings, support informed public debate, and promote prevention and patient-centred solutions in oncology and haematology care.

The All.Can Poland initiative operates thanks to the financial support of Bristol Myers Squibb (its main sponsor) and Amgen, Eli Lilly, Gilead, and Takeda.





## Achievements in 2025

Championing strategic, evidence-based insights, All.Can Romania achieved a major policy impact in 2025. Six of the sixteen recommendations included in the *Analysis Report on Cancer Care Efficiency*, launched in March, were incorporated into the national health reform plan adopted by the authorities during the year. This represents a concrete step toward influencing policy agendas and reframing the public debate on improving cancer care, marking one of the most significant accomplishments of the All.Can Romania initiative.

To accelerate the implementation of solutions, All.Can Romania organised preparatory technical debates. These focused on disseminating both short-term and long-term recommendations from the *Analysis Report*, with the objective of improving resource efficiency across Romania's oncology system.

The launch event of the *Analysis Report on Cancer Care Efficiency* demonstrated strong stakeholder engagement and policy relevance. Attendance included representatives from public authorities, patient representatives, macroeconomic and health experts, healthcare professionals and physicians, along with members of the local All.Can Romania initiative.

A total media reach of over 1.8 million people across two national television stations, one national radio station, three local publications, and more than 15 online media platforms — both generalist and specialised — achieved significant public visibility. These efforts substantially contributed to shaping the public narrative around cancer care efficiency.

All.Can Romania also contributed to high-level public discourse through participation in major national events, including the Health Forum in July and The Initiative for Women's Health in November, both held in Bucharest.

To further amplify stakeholder voices, video messages supporting All.Can Romania's actions — featuring both members and external stakeholders — were published on the local initiative's website as part of the "1 Minute for Change — Wall of Action".

In 2025, the local network expanded to 13 committed members, welcoming three new partners: Novartis, IQVIA Romania, and the C.O.M.P.A.S. Association, further strengthening the initiative's multidisciplinary foundation.

At the end of the year, All.Can Romania launched the Mission Early project, aimed at defining effective public policies for early cancer care. The initiative focuses on mapping the so-called "Lavender Zone", where lavender serves as a symbol of solidarity and support for people living with cancer.

Mission Early was initiated in October 2023 and includes research collaboration with the Centre for Research on Health and Social Care (CERGAS) at SDA Bocconi University in Milan. Throughout the research process, Mission Early has provided strategic expertise and guidance. Two dedicated studies focused on Romania are nearing completion, and their findings — offering valuable data and insights into early cancer care — are expected to be presented and analysed in early 2026.

## 2026 Outlook

Looking ahead, All.Can Romania will continue to advance thought leadership at a time when Romania's healthcare system faces increasing pressures and future uncertainties. These challenges call for coordinated responses and intensified action to improve cancer care outcomes.

All.Can's leadership and strategic engagement remain essential to ensuring continued, meaningful progress. Maintaining momentum is critical to leveraging the initiative's established framework as a credible and impactful force in Romania's oncology landscape.

With the National Cancer Control Plan serving as a key strategic instrument, All.Can Romania will focus on accelerating implementation and translating policy into tangible progress. The initiative will continue to prioritise enhanced resource efficiency in the oncology system by keeping key stakeholders actively engaged, aligning existing resources, and further consolidating the All.Can Romania framework – ultimately driving sustainable improvements in cancer care and quality of life for patients across Romania.





## Achievements in 2025

In 2025, All.Can Spain carried out important events, all focused on detecting inefficiencies in the oncology care circuit, improving the care of cancer patients and optimising cancer care pathways. Some of these events were:

4. Promotion of a Parliamentary Initiative in Congress: In February, All.Can Spain presented a joint parliamentary initiative in the Congress of Deputies, outlining key proposals to transform cancer care in Spain in the context of World Cancer Day.
5. All.Can Spain held a key workshop in Bilbao, the Basque Country, also in February, together with the Basque Health Service, Osakidetza. The focus was the implementation of the latest EU recommendations on cancer screening. At this event, and in the presence of senior officials of the Regional Ministry of Health, experts such as Isabel Mosquera-Metcalf and Dr. Rafael López, a member of the All.Can Spain Scientific Committee, shared their perspectives on advances in early detection and current tools to improve diagnostics. Mrs. Maite Martinez, Osakidetza's Health Care Director, opened the event, which also featured the participation of the Deputy Minister of Health and Digital Transformation, Mr. Gontzal Tamayo, among other prominent speakers from the Department of Health of Euskadi. Additionally, patients were represented by the Euskadi delegation of the Spanish Association Against Cancer.
6. All.Can Spain completed the elaboration of the platform's third report. This focused on long-term cancer survivors — a group of patients that has significantly increased in recent years due to advances in early detection, more effective treatments, and improvements in clinical follow-up. This

document concludes the trilogy of studies conducted by All.Can Spain, which address various stages of the oncology care pathway, from suspected cancer to diagnosis, diagnosis and treatment, to the management of long-term survivors. As with previous reports, this study was developed in line with All.Can's core principle of identifying system inefficiencies and proposing evidence-based recommendations to improve patient experience across all stages of care.

7. In October, the Platform hosted a press conference in Madrid, Spain, to present the third report, which called for a comprehensive National Plan for Long-Term Cancer Survivors, including recommendations to enhance patient care. The in-person session brought together journalists from major Spanish media outlets, including health correspondents, as well as members of the All.Can Spain Scientific Committee, achieving more than 24 media impacts.





## Achievements in 2025

In 2025, All.Can Sweden worked on several initiatives to strengthen cancer care and advance policy discussions. During the year, the organisation participated in key national arenas, including Almedalen, Sweden's annual political week. All.Can Sweden also took part in Vitalis, the leading Nordic conference on e-Health and the future of healthcare, focused on innovation, digitalisation, and cross-sector collaboration.


Also, during 2025, All.Can Sweden worked to accelerate the implementation of lung and prostate cancer screening in Sweden. The initiative focused on strengthening the evidence base, engaging key stakeholders, and raising awareness through targeted reports, webinars, and discussions.

At the beginning of the year, All.Can Sweden published a report outlining the status of lung and prostate cancer screening in Sweden. This report served as a foundation for dialogue and activities throughout the year.

A webinar on lung cancer screening highlighted recent developments and the importance of early detection. In addition, a meeting/webinar on prostate cancer screening held in Gothenburg brought together stakeholders to exchange knowledge and explore future screening approaches.

These efforts contributed to building momentum for urgently needed improvements in Sweden's cancer screening strategy, particularly in light of the EU recommendation. The initiatives fostered cross-sector dialogue and laid out the groundwork for future pilot programs, policy development, and stronger interregional cooperation to reduce screening inequities and improve public awareness.





## Achievements in 2025

In 2025, All.Can Switzerland focused on turning evidence and dialogue into concrete, system-level action.

A major milestone was the development of national consensus recommendations on Cancer Survivorship Care. More than 50 experts from different disciplines, together with patient representatives, worked through a structured consensus process to define shared quality principles for survivorship care in Switzerland. The recommendations provide a common reference point for coordinated, people-centred follow-up care and are now available as an orientation framework across the system.

Building on this work, All.Can Switzerland contributed input to the National Cancer Plan 2026–2032. Following a multi-stakeholder workshop on efficiency and equity in cancer care, insights from practice were systematically combined with the principles of the All.Can *Action Guide*. This resulted in a set of concrete, implementation-oriented recommendations

aimed at strengthening people-centred care, coordination and efficient resource use at national level.

In parallel, All.Can Switzerland conducted a structured analysis of the cancer patient pathway, identifying gaps, inefficiencies and breakpoints along the care journey. Together with its members, the organisation prioritised implementation fields based on patient benefit, feasibility and system impact, creating a clear bridge from analysis to action.

Finally, All.Can Switzerland actively contributed to cross-border exchange within the DACH network, sharing experiences with sister organisations in Germany and Austria and helping to align national developments with broader All.Can priorities.

Together, these activities strengthened All.Can Switzerland's role as a platform for multi-stakeholder dialogue, system analysis and practical implementation in cancer care.

**Join us. Work with us. Together, we All.Can.**

**All.Can International**  
**Rue du Luxembourg 22-24**  
**BE-1000 Brussels**  
**secretariat@all-can.org**  
**www.all-can.org**

 **All.Can**

 **@AllCanGroup**

All.Can International is a not-for-profit organisation (ASBL) registered in Belgium.

Its work is made possible with financial support from Bristol Myers Squibb, Roche, MSD, Johnson & Johnson, Pfizer, Astellas, and Daiichi Sankyo, among other funding means.



**Changing cancer care together**